Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer
Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer
The scope of the trial is to assess the efficacy of the association gemcitabine-cisplatin +
 radiotherapy followed by an adjuvant chemotherapy
Inclusion Criteria:

 -  Age between 18 and 70 years old

 -  Cervical uterine cancer (epidermoid or adenocarcinoma, stage:from IB> or = 4 cm to IV,
 according to FIGO classification) histologically proven

 -  Measurable lesions,clinically and by MRI assessed

 -  PS-WHO < or = 2 ou Karnofsky Index >70 per cent

 -  Life expectancy > 3 months

 -  Hematologic function: leukocytes < or = 3 G/l, polynuclear neutrophil leukocytes > or
 = 1.5 G/l, platelets > or = 100 G/l, hemoglobin > or = 10 g/dl

 -  Hepatic function: ASAT and ALAT < 2.5 ULN

 -  Renal function: creatininemia < 1.5 ULN, clearance > 60 ml/min

 -  No prior chemotherapy or radiotherapy

 -  Contraception

 -  Written informed consent signed

 Exclusion Criteria:

 -  Stage IB < 4 cm or IVB

 -  Other histology than epidermoid or adenocarcinoma

 -  Distant metastases, including sus-clavicular adenopathy

 -  Contraindication to MRI

 -  Pregnant or lactating woman

 -  Auto-immune disease

 -  Peripheric neuropathy, autograft or homograft, psychiatric disease

 -  Prior cancer (except cutaneous basocellular carcinoma and uterine cervical carcinoma
 in situ)

 -  Active infection

 -  Other clinical trial with an experimental drug

 -  Known positive serology (HIV, HbC, HbS)